Literature DB >> 2924377

Elevated plasma tamoxifen levels in a patient with liver obstruction.

M W DeGregorio, V J Wiebe, A P Venook, W M Holleran.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2924377     DOI： 10.1007/BF00267955

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  8 in total

1.  High-dose chemotherapy for breast cancer.

Authors:  P P Carbone
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

Review 2.  New agents and new medical treatments for advanced breast cancer.

Authors:  I C Henderson; D F Hayes; S Come; J R Harris; G Canellos
Journal:  Semin Oncol       Date:  1987-03       Impact factor: 4.929

3.  Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.

Authors:  E A Eisenhauer; D M Bowman; K I Pritchard; A H Paterson; J Ragaz; I Plenderleith; P H Geggie; I Maxwell
Journal:  Cancer Treat Rep       Date:  1984-11

4.  A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.

Authors:  M E Lippman; J Cassidy; M Wesley; R C Young
Journal:  J Clin Oncol       Date:  1984-01       Impact factor: 44.544

5.  A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

Authors:  J C Allegra; T M Woodcock; S P Richman; K I Bland; J L Wittliff
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

6.  Effects of estradiol and tamoxifen on human breast cancer cells in serum-free culture.

Authors:  P D Darbre; S Curtis; R J King
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

7.  Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors.

Authors:  V Hug; D Johnston; M Finders; G Hortobagyi
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

8.  Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity.

Authors:  C Benz; D Gandara; B Miller; T Drakes; S Monroe; B Wilbur; M DeGregorio
Journal:  Cancer Treat Rep       Date:  1987-03
  8 in total
  6 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer.

Authors:  J Maenpaa; V Wiebe; S Koester; G Wurz; V Emshoff; R Seymour; P Sipila; M DeGregorio
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Topical toremifene: a new approach for cutaneous melanoma?

Authors:  J Maenpaa; T Dooley; G Wurz; J VandeBerg; E Robinson; V Emshoff; P Sipila; V Wiebe; C Day; M DeGregorio
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  A case-control study of non-alcoholic fatty liver disease in breast cancer.

Authors:  Ahmet Bilici; Mustafa Ozguroglu; Ismail Mihmanli; Hande Turna; Ibrahim Adaletli
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

6.  Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis.

Authors:  Feng Guo; Qingfeng Fu; Yang Wang; Guoqing Sui
Journal:  J Cell Mol Med       Date:  2019-07-14       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.